SLC5A2 and type 2 diabetes mellitus: It is therefore notable that the incidence of sight threatening retinopathy was significantly decreased in type 2 diabetic patients treated with SGLT2 inhibition compared to DPP4 inhibition, pioglitazone or sulfonylureas (53).